The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

The funding, which ranks as one of the largest of its kind for a China-based drug startup, will support a portfolio of multifaceted antibodies the company believes to be advances over existing ...

Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead ...

As part of a larger review, analyst Leonid Timashev identified 13 companies that could see deal interest as well as more than ...

Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.

The ruling, related to a lawsuit from several major medical organizations, stated that HHS ignored established protocols in altering the childhood immunization schedule and overhauling a key CDC panel ...

The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat ...

The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement ...

The trial clearance for Shanghai-based Unixell is another step forward for the rapidly advancing Chinese biotech ecosystem, ...

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...

Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.

Combining the disparate databases used to detect potential issues with drugs, vaccines and other products into a single dashboard will enhance their utility and cut costs, the agency said.